

Date: 12/08/2025

To,  
The Board of Directors,  
Ishita Drugs & Industries Limited,  
Ahmedabad.


### LIMITED REVIEW REPORT

We have reviewed the accompanying of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LIMITED** for the period **01 Apr 2025 to 30 Jun 2025**. (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of **Interim financial information performed by the Independent auditor of the entity issued by the Institute of Chartered Accountants of India**. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribe under section 133 of companies Act, 2013 read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of  
**JAYMIN SHAH & ASSOCIATES**



**CA Mayank Sancheti**

M No. :170863

Date: 12/08/2025

Place: Ahmedabad

UDIN: 25170863BMLNHH4674

ISHITA DRUGS AND INDUSTRIES LIMITED  
CIN: L24231GJ1992PLC017054  
Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand  
Ahmedabad – 382170  
Website: www.ishitadrugs.com  
Contact: +91 7226995613

**Unaudited Financial Results for the Quarter Ended June 30, 2025**

Amount in Lacs except Per Share data

Particulars	Figures for 3 Months Ended	Figures for Preceding 3 Months Ended	Figures for Corresponding 3 Months in the previous Year Ended	Figures for the previous year Ended
	Un-audited	Audited	Un-audited	Audited
	30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25
<b>1 INCOME</b>				
Revenue from Operations	540.05	456.36	302.76	1499.73
Other Income	9.11	15.99	5.83	33.57
<b>Total Income</b>	<b>549.16</b>	<b>472.35</b>	<b>308.59</b>	<b>1533.30</b>
<b>2 EXPENSES</b>				
(a) Cost of Material Consumed	379.59	315.06	185.21	1010.94
(b) Purchase of Stock-In-Trade	23.92	23.79	4.30	33.71
(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	1.41	17.99	18.07	23.56
(d) Employee Benefit Expense	33.60	31.86	34.39	134.43
(e) Finance Cost	2.33	4.27	0.78	7.22
(f) Depreciation, Depletion and Amortisation Expense	2.75	2.60	2.79	10.98
(g) Other Expense	66.83	38.51	43.41	196.93
<b>Total Other Expenses</b>	<b>66.83</b>	<b>38.51</b>	<b>43.41</b>	<b>196.93</b>
<b>Total Expenses</b>	<b>510.43</b>	<b>434.09</b>	<b>288.96</b>	<b>1417.78</b>
<b>3 Total Profit before Exceptional Items and Tax</b>	<b>38.73</b>	<b>38.25</b>	<b>19.64</b>	<b>115.52</b>
<b>4 Exceptional Items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>5 Total Profit before Tax</b>	<b>38.73</b>	<b>38.25</b>	<b>19.64</b>	<b>115.52</b>
<b>6 Tax Expense</b>				
<b>7 Current Tax</b>	<b>8.50</b>	<b>10.25</b>	<b>4.90</b>	<b>29.50</b>
<b>8 Deferred Tax</b>	<b>0.00</b>	<b>(0.79)</b>	<b>0.00</b>	<b>(0.79)</b>
<b>9 Total Tax Expenses</b>	<b>8.50</b>	<b>9.46</b>	<b>4.90</b>	<b>28.71</b>
<b>10 Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement</b>	<b>0.00</b>		<b>0.00</b>	<b>0.00</b>
<b>11 Net Profit Loss for the period from continuing operations</b>	<b>30.23</b>	<b>28.80</b>	<b>14.74</b>	<b>86.81</b>

*Jaydinapawel*




12	Profit / (Loss) from discontinued operations before tax	0.00	0.00	0.00	0.00
13	Tax Expenses of discontinued operations	0.00	0.00	0.00	0.00
14	Net Profit / (Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00
15	Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00
16	<b>Total Profit / (Loss) for the period</b>	<b>30.23</b>	<b>28.80</b>	<b>14.74</b>	<b>86.81</b>
17	Other Comprehensive Income net of Taxes	0.00	0.00	0.00	0.00
18	<b>Total Comprehensive Income for the Period</b>	<b>30.23</b>	<b>28.80</b>	<b>14.74</b>	<b>86.81</b>
19	<b>Total profit or loss attributable to</b>				
	Profit or loss, attributable to owners of parents	0.00	0.00	0.00	0.00
	Total Profit or loss, attributable to non-controlling interests	0.00	0.00	0.00	0.00
20	<b>Total comprehensive income for the period attributable to</b>				
	Comprehensive Income for the period attributable to the owners of parents	0.00	0.00	0.00	0.00
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0.00	0.00	0.00	0.00
21	<b>Details of Equity Share Capital</b>				
	Paid-Up Equity Share Capital	299.03	299.03	299.03	299.03
	Face Value of Equity Share Capital	10.00	10.00	10.00	10.00
22	<b>Details of Debt Securities</b>				
	Paid-Up Debt Capital	0.00	0.00	0.00	0.00
	Face Value of Debt Securities	0.00	0.00	0.00	0.00
23	Reserves Excluding Revaluation Reserves	0.00	0.00	0.00	0.00
24	Debenture Redemption Reserve	0.00	0.00	0.00	0.00
25	<b>Earnings Per Share</b>				
(i)	<b>Earnings Per Share for continuing operations</b>				
	Basic Earnings / (Loss) per share from continuing operations	1.01	0.96	0.49	2.90
	Diluted Earnings / (Loss) per share from continuing operations	1.01	0.96	0.49	2.90
(ii)	<b>Earnings Per Share for discontinued operations</b>				
	Basic Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00
	Diluted Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00
(iii)	<b>Earnings per Equity Share</b>				
	Basic Earnings / (Loss) per share from continuing and discontinued operations	1.01	0.96	0.49	2.90
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	1.01	0.96	0.49	2.90
26	Debt Equity Ratio	0.00	0.00	0.00	0.00
27	Debt Service Coverage Ratio	0.00	0.00	0.00	0.00
28	Interest Service Coverage Ratio	0.00	0.00	0.00	0.00

*Jaydevi Agrawal*



**NOTES**

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on August 12, 2025.
2. The Limited Review of the results has been completed by the Statutory Auditors of the Company.
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
4. The financial results for the quarter ended 30th June, 2025 are Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
6. Results are available at Company's website [www.ishitadrugs.com](http://www.ishitadrugs.com) and also at [www.bseindia.com](http://www.bseindia.com).

For, **ISHITA DRUGS AND INDUSTRIES LIMITED**  
**JAGDISH AGRAWAL**Place **Ahmedabad****MANAGING DIRECTOR**Date **12-Aug-25****DIN: 01031687**